Novo Nordisk is looking to partner with digital companies at every stage of the weight loss journey to help patients lose weight more effectively and stay on track with its flagship medication, Wegovy (semaglutide).
The Novo Nordisk Partner Platform (NNPP) was announced at HLTH Europe, taking place in Amsterdam from 16 to 19 June, by Anne Cathrine Fleischer, vice president of Global Obesity Consumer Engagement and New Business Models at Novo Nordisk.
Go deeper with GlobalData
Fleischer said that the programme will provide more services for patients receiving its glucagon-like peptide 1 receptor agonist (GLP-1RA) semaglutide, which is marketed as Wegovy for weight loss and Ozempic in type 2 diabetes, including fitness and dietary advice.
Fleischer explained: “The idea is that we create this ecosystem or marketplace of selected solutions that people can pick and choose from, so when a patient has started treatment, we know they have received help. We know when we look at our own digital tools that when intervention is combined with those efficient weight loss medications, patients are receiving better weight loss, so we hope we can significantly improve outcomes by combining education with digital tools.”
Fleischer said that while this will be available to patients through the Novo Nordisk website or Novo Care, there are also considerations to work with an app developer to ensure all the services are available in one place.
“By partnering with these players, we can provide a much better patient journey and care pathway,” Fleischer added.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataNovo Nordisk is hoping to partner with a company which uses artificial intelligence (AI) to scan a person’s plate of food and provide them with information as to whether it is providing the necessary nutrition, notably protein, due to GLP-1RAs’ association with loss of muscle mass. Novo Nordisk is also in conversation with a company offering a body composition scanner mobile app.
The pharma giant is also seeking telehealth providers and pharmacies to provide medical advice to patients receiving the therapy.
Novo Nordisk aims to cement itself as the leading weight loss company globally after Eli Lilly announced its therapy Zepbound (tirzepatide) resulted in more weight loss than Wegovy in a Phase III study.
Earlier in June, Novo Nordisk accelerated its subcutaneous and oral versions of amycretin into Phase III trials for patients with obesity and overweight. It recently initiated two more Phase III trials of its candidate CagriSema, as well as inking an $812m partnership with Deep Apple Therapeutics to access novel compounds, not GLP-1RAs, for obesity and other diseases. The company also announced a partnership with tech heavyweight NVIDIA to advance drug discovery using cutting-edge AI technologies.
